Spotlight – Seeking target selectivity in achondroplasia
As Bridgebio appears to validate FGFR3 as a target in achondroplasia, who else might follow suit?
Spotlight – What's next in Nash
The next few months will see some important mid-stage Nash results, from Viking, 89Bio, Northsea and others.
Spotlight – Cystic fibrosis developers take a deep breath
The next couple of years should show whether inhaled genetic projects have potential.
US deal watchdog's bark could be worse than its bite
Chills in the biopharma M&A market are frequently blamed on the FTC. But is the agency really stopping deals from happening?
Spotlight – still plenty of hopefuls in lung fibrosis
Roche’s zinpentraxin alfa is out of the running, but Bristol, Blade, Pliant and others have contenders in the mid-stage idiopathic pulmonary fibrosis pipeline.
The slow death of the medtech Spac deal
The remarkable thing is that these tie-ups are still occurring, so atrocious is their track record.
A renewed push into early bladder cancer
Ferring's Adstiladrin has joined Keytruda with a US approval, but it might not be the answer doctors are looking for.
Immuno-oncology goes subcutaneous
A pivotal study of Keytruda’s SC formulation is about to read out, but Roche could get to market first.
The biggest-selling drugs of 2023
Move over Comirnaty: Keytruda takes top spot as its indications broaden and demand for Covid vaccines recedes.
